• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA to assess drugmakers’ websites

FDA to assess drugmakers’ websites

April 28, 2011
CenterWatch Staff

U.S. drug regulators will scrutinize consumer reactions to websites for prescription drugs in an attempt to research how to apply advertising rules to social media, according to a Bloomberg report. 

The FDA may issue rules this year outlining how drugmakers can post more tweets and online videos without violating marketing rules written for print, radio and television. Prescription drug ads pushing a product's benefits must also provide information about risks.  Slow sales and high costs are forcing manufacturers to find cheaper ways to advertise, such as using the social media sites Twitter and Facebook.

The FDA proposed the agency conduct three studies in which participants would view a website advertising a fictitious drug and then answer questions regarding information about a drug.  The studies will examine whether personal testimonial videos posted on a site influenced consumer perceptions of a product. The FDA will also investigate whether the participants understand possible side effects of the drug after reading about risk information on a website.

“Currently, there are a number of questions surrounding how to achieve ‘fair balance’” in online direct-to-consumer promotions, the agency said. The proposed web-advertising studies are “relevant to current policy questions and debate and will complement qualitative research we plan to conduct on issues surrounding social media.”

The FDA reported that “risk information is often presented less prominently and in fewer locations on the website” as opposed to the information about drug benefits. Moreover, the agency indicated that side effects and risks are “often incomplete and written at very high literacy levels.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing